Meeting
2023 ASCO Annual Meeting
Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center.
Authors
Kelly Sharon Chien
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Kelly Sharon Chien , Faustine Ong , Kunhwa Kim , Ziyi Li , Rashmi Kanagal-Shamanna , Courtney Denton Dinardo , Koichi Takahashi , Guillermo Montalban-Bravo , Danielle Hammond , Koji Sasaki , Sherry Pierce , Hagop M. Kantarjian , Guillermo Garcia-Manero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Other Leukemia, Myelodysplastic Syndromes, and Allotransplant
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7072)
DOI
10.1200/JCO.2023.41.16_suppl.7072
Abstract #
7072
Poster Bd #
202
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays.
First Author: Catherine Callaghan Coombs
Poster
2023 ASCO Annual Meeting
Clonal hematopoiesis (CH) associated mutations in patients with advanced solid tumors enrolled in phase I clinical trials.
First Author: Julieta Rodriguez
Poster
2023 ASCO Annual Meeting
Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.
First Author: Jeffrey Lee Jensen
Poster
2021 ASCO Annual Meeting
Prevalence of inferred clonal hematopoiesis (CH) detected on comprehensive genomic profiling (CGP) of solid tumor tissue or circulating tumor DNA (ctDNA).
First Author: Emmanuel S. Antonarakis